These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 19472560)

  • 1. FDA, industry collaborate to strengthen painkiller restrictions.
    Sipkoff M
    Manag Care; 2009 Apr; 18(4):10-1. PubMed ID: 19472560
    [No Abstract]   [Full Text] [Related]  

  • 2. Criminal conviction for distribution of a drug not approved by the FDA.
    Brushwood DB
    Am J Hosp Pharm; 1991 Apr; 48(4):747-9. PubMed ID: 2042679
    [No Abstract]   [Full Text] [Related]  

  • 3. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 4. A difficult balance--pain management, drug safety, and the FDA.
    Woodcock J
    N Engl J Med; 2009 Nov; 361(22):2105-7. PubMed ID: 19940297
    [No Abstract]   [Full Text] [Related]  

  • 5. Playing "kick the FDA"--risk-free to players but hazardous to public health.
    Wood AJ
    N Engl J Med; 2008 Apr; 358(17):1774-5. PubMed ID: 18434649
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA and congress: differing agendas?
    Lipman AG
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):116-7. PubMed ID: 20504131
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA acts to reduce harm from opioid drugs.
    J Pain Palliat Care Pharmacother; 2011; 25(3):296-7. PubMed ID: 21882983
    [No Abstract]   [Full Text] [Related]  

  • 8. Trying times at the FDA--the challenge of ensuring the safety of imported pharmaceuticals.
    Schweitzer SO
    N Engl J Med; 2008 Apr; 358(17):1773-7. PubMed ID: 18434648
    [No Abstract]   [Full Text] [Related]  

  • 9. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT
    J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
    [No Abstract]   [Full Text] [Related]  

  • 10. Reducing opioid. analgesic abuse: models for successful collaboration among government, industry and other key stakeholders.
    Smith MY; Kleber HD; Katz N; Houck LK; Sabo A
    Drug Alcohol Depend; 2008 May; 95(1-2):177-81. PubMed ID: 18484109
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA actions to prevent prescription drug abuse.
    Jeske AH
    Tex Dent J; 2005 Jul; 122(7):634-45. PubMed ID: 16152888
    [No Abstract]   [Full Text] [Related]  

  • 12. Rehabilitating opioid regulation: a prescription for the FDA's next proposal of an opioid risk evaluation and mitigation strategy (REMS).
    Homenko H
    Health Matrix Clevel; 2012; 22(1):273-313. PubMed ID: 22616548
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA panel recommends tighter rules for prescribing opioids.
    McCarthy M
    BMJ; 2013 Feb; 346():f1012. PubMed ID: 23412738
    [No Abstract]   [Full Text] [Related]  

  • 14. Maker of growth hormone feels long arm of law.
    Nordenberg T
    FDA Consum; 1999; 33(5):33. PubMed ID: 10522170
    [No Abstract]   [Full Text] [Related]  

  • 15. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
    Hubbard WK
    Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
    [No Abstract]   [Full Text] [Related]  

  • 16. A sick agency in need of a cure? Recall of a popular pain drug has focused attention on government drug regulation.
    Spake A
    US News World Rep; 2004 Dec; 137(21):32-3, 36. PubMed ID: 15636503
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceutical product integrity: can the FDA assure quality?
    Bernstein I
    Manag Care; 2004 Mar; 13(3 Suppl):30-3. PubMed ID: 15074168
    [No Abstract]   [Full Text] [Related]  

  • 18. Healthcare professionals and the DEA: trying to get back in balance.
    Heit HA
    Pain Med; 2006; 7(1):72-4. PubMed ID: 16533201
    [No Abstract]   [Full Text] [Related]  

  • 19. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
    Willis KD
    Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
    [No Abstract]   [Full Text] [Related]  

  • 20. The goals of FDA regulation and the challenges of meeting them.
    Tyler RS
    Health Matrix Clevel; 2013; 22(2):423-31. PubMed ID: 23668096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.